Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA Therapeutic Drug Targeting CD19 for Hematologic Malignancies
NCT07349849Phase 1Recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Dec 2025
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of in vivo CD19-targeted CAR-T mRNA-LNP therapy in B-cell malignancy, sponsored by Xinqiao Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 3 months. Started Dec 2025; status: recruiting.
02
Drugs
in vivo CD19-targeted CAR-T mRNA-LNP therapy
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on NCT07349849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349849.